Gilead Sciences Inc
NASDAQ:GILD
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
62.79
97.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Gilead Sciences Inc
Gilead Sciences Inc
Income to Minority Interest
Gilead Sciences Inc
Income to Minority Interest Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income to Minority Interest | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income to Minority Interest
$12m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income to Minority Interest
-$11m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income to Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Income to Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income to Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income to Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
Glance View
Gilead Sciences Inc. is a biopharmaceutical company that has carved a significant niche in the healthcare industry by focusing on the discovery, development, and commercialization of innovative medicines. Founded in 1987 and based in Foster City, California, Gilead has gained prominence for its groundbreaking antiviral therapies, particularly in the field of HIV and hepatitis C. The company transformed the landscape of these diseases with its flagship products, among them Truvada and Harvoni, which have been instrumental in improving patient outcomes and generating substantial revenues. Gilead continues to build on its legacy by expanding its research into oncology, inflammatory diseases, and cardiovascular conditions, positioning itself as a leader in addressing some of the world's most pressing health challenges. For investors, Gilead Sciences represents a compelling opportunity amid a rapidly evolving pharmaceutical market. The company’s robust pipeline of candidates and ongoing research into novel therapeutic areas suggest potential for sustained growth and profitability. With a strong commitment to innovation, Gilead is not only focused on maximizing the utility of its existing treatments but is also exploring partnerships and acquisitions to bolster its drug development capabilities. As the global demand for effective treatments rises, Gilead stands to benefit from its established reputation, financial resilience, and strategic investments, making it a noteworthy consideration for those looking to invest in a company that is dedicated to improving health outcomes worldwide.
See Also
What is Gilead Sciences Inc's Income to Minority Interest?
Income to Minority Interest
12m
USD
Based on the financial report for Sep 30, 2024, Gilead Sciences Inc's Income to Minority Interest amounts to 12m USD.
What is Gilead Sciences Inc's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 10Y
-6%
Over the last year, the Income to Minority Interest growth was -74%. The average annual Income to Minority Interest growth rates for Gilead Sciences Inc have been -22% over the past three years , -4% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet
